Mydecine Innovations Group Inc. (MYCOF)
| Market Cap | 172.92K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.19M |
| Shares Out | 61.76M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 346 |
| Average Volume | 2,804 |
| Open | 0.0028 |
| Previous Close | 0.0040 |
| Day's Range | 0.0028 - 0.0028 |
| 52-Week Range | 0.0007 - 0.0160 |
| Beta | 2.18 |
| RSI | 46.40 |
| Earnings Date | Aug 20, 2025 |
About MYCOF
Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005 a family of psilocin analogs. The company also develops MYCO-006 a family of MDMA analogs and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery,... [Read more]
Full Company ProfileNews
Mydecine Innovations Group Provides Update On Annual Financial Statements
Vancouver, British Columbia, June 26, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management...
Mydecine Innovations Group Provides Update on Annual Financial Statements
Vancouver, British Columbia – TheNewswire - June 12, 2025 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a managemen...
Mydecine Innovations Group Provides Update on Annual Financial Statements
Vancouver, British Columbia – TheNewswire - May 29, 2025 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management...
Mydecine Innovations Group Provides Update on Annual Financial Statements
Vancouver, British Columbia – TheNewswire - May 15, 2025 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management...
Mydecine Innovations Group Announces Late Filing Of Annual Financial Statements And Management Cease Trade Order
Vancouver, British Columbia, May 01, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) announces today that as a result of delays to its audit, ...
Mydecine Innovations Group Announces Changes To Board And Management
Vancouver, British Columbia, March 26, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce the appointments of Mr. Peter ...
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology comp...
Mydecine Innovations Group Announces Director Resignation
VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology c...
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
VANCOUVER, British Columbia, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology co...
Mydecine Announces Update Regarding the Special Access Program
DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovativ...
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engin...
Mydecine Provides Q4 2023 Business Update
VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engi...
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
VANCOUVER, British Columbia, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the n...
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the ...
Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing
VANCOUVER, British Columbia, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the...
Mydecine Innovations Announces Closing of Prospectus Supplement Financing
VANCOUVER, British Columbia, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the ...
Mydecine Innovations Group Files Prospectus Supplement
VANCOUVER, British Columbia, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the ...
Mydecine Announces Conditional Approval of CSE Listing
VANCOUVER, British Columbia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO:MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), is pleased to announce that it has mad...
Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023
VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company engineering the next wave of i...
Mydecine Innovations Group Provides Corporate Update
VANCOUVER, British Columbia, July 21, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the n...
Mydecine Reports its Special Meeting Results
VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the ...
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the ne...
Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023
VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company engineering the nex...
Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the n...
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
VANCOUVER, British Columbia, April 24, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the...